Tag: Phase
Conclusions S-1 plus docetaxel combination therapy in an outpatient setting provided promising activity with acceptable adverse toxicities.
Content Type Journal ArticleDOI 10.1007/s00280-010-1433-7Authors
Chikara Kunisaki, Department of Surgery, Gastroenterological Center, Yokohama City University, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024 JapanMasazumi Takahashi, Department of Surgery, Yokohama Municipal Hospital, 56 Okazawa-cho, Hodogaya-ku, Yokohama, 240-0062 JapanHirochika Makino, Department of Surgery, Gastroenterological Center, Yokohama City University, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024 JapanTakashi Oshima, Department of Surgery, Gastroenterological Center, Yokohama City University, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024 JapanShoichi …
Source: MedWorm: Oral Cancer
Tags: Advanced, Biweekly, Cancer, chemotherapy., Combination, docetaxel, FirstLine, Gastric, Phase, Study, Treatment
Posted in Treatment | No Comments »
Conclusion The SOx regimen evidenced a relatively high response rate and was well tolerated as a first-line therapy for advanced gastric
cancer.
Content Type Journal ArticleDOI 10.1007/s10637-010-9507-2Authors
Sung Yong Oh, Department of Internal Medicine, Dong-A University College of Medicine, Busan, KoreaHyuk-Chan Kwon, Department of Internal Medicine, Dong-A University College of Medicine, Busan, KoreaSang-Ho Jeong, Departments of Surgery, Gyeongsang National University Hospital, Jinju, South KoreaYoung-Tae Joo, Departments of Surgery, Gyeongsang National University Hospital, Jinju, South KoreaYoung-Joon Lee, Departments of Surgery, Gyeongsang National University Hospital, Jinju, South KoreaSu hee Cho, Departments of Internal Medicine, Gyeongsang National University Hospital, Ji…
Source: MedWorm: Oral Cancer
Tags: Advanced, Cancer, chemotherapy., Combination, FirstLine, Gastric, oxaliplatin, patients, Phase, Study, therapy
Posted in Treatment | No Comments »
Summary Sunitinib is associated with a robust objective response rate in patients with metastatic clear cell renal cell carcinoma
(RCC). The primary objective of this phase II clinical trial was to assess the overall response rate for sunitinib in patients
with papillary metastatic RCC as well as other non-clear cell histologies. A Simon 2-stage design was used to determine the
number of papillary metastatic RCC patients for enrollment, and allowed for descriptive response data for other non-clear
cell histologies. Twenty-three patients were enrolled, including 8 with papillary renal cell carcinoma (RCC) and the remainder
with other non-clear cell histologies (unclassified in 5 patients). All patients received 50 mg of oral sunitinib in cycles
of 4 weeks followed…
Source: MedWorm: Oral Cancer
Tags: carcinoma, cell, Metastatic, nonclear, patients, Phase, renal, Sunitinib, Trial
Posted in Treatment | No Comments »
Conclusion
Combination chemotherapy with bevacizumab and erlotinib showed clinical activity with infrequent grade 3 and 4 adverse effects in patients with advanced biliary cancers. On the basis of preliminary molecular analysis, presence of a k-ras mutation may alter erlotinib efficacy. The combination of bevacizumab and erlotinib may be a therapeutic alternative in patients with advanced biliary cancer. (Source: Journal of Clinical Oncology)
Source: MedWorm: Oral Cancer
Tags: Bevacizumab, Biliary, Biweekly, Cancer, Combination, consortium, Daily, Erlotinib, Gastrointestinal, Multicenter, patients, Phase, Report, Study, Testing, Trial, Unresectable
Posted in Treatment | No Comments »
First-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) is usually limited to four to six cycles. Maintenance therapy can delay progression and prolong survival. The oral epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib has proven efficacy and tolerability in second-line NSCLC. We designed the phase 3, placebo-controlled Sequential Tarceva in Unresectable NSCLC (SATURN; BO18192) study to assess use of erlotinib as maintenance therapy in patients with non-progressive disease following first-line platinum-doublet chemotherapy. (Source: The Lancet Oncology)
Source: MedWorm: Oral Cancer
Tags: Advanced, articles, Cancer, Erlotinib, lung, maintenance, multicentre, nonsmallcell, Phase, placebocontrolled, randomised, Study, Treatment
Posted in Treatment | No Comments »
In a phase 3 study, the authors assessed the effects of dasatinib at doses of 140 mg once daily and 70 mg twice daily in patients who had either chronic myeloid leukemia (CML) in advanced phases or Philadelphia chromosome-positive acute lymphoblastic leukemia and were resistant or intolerant to imatinib. In the current report, the results for patients with CML in blast phase after 2 years of follow-up are reported.Patients were stratified according to whether they had CML in myeloid blast phase (MBP-CML) or in lymphoid blast phase (LBP-CML) and were randomized (1:1) within each stratum to receive either oral dasatinib 140 mg once daily or 70 mg twice daily.In patients with MBP-CML, the major hematologic response rate was 28% for both regimens; and, in patients with LBP-CML, the major hemat…
Source: MedWorm: Oral Cancer
Tags: after, blast, Chronic, Dasatinib, followup, imatinibintolerant, imatinibresistant, leukemia, myeloid, Phase, Study, years
Posted in Treatment | No Comments »
Conclusion: Single-agent oral vinorelbine is extremely safe in elderly patients with advanced NSCLC and ECOG PS of two or more and may represent a valid option in this very special population. (Source: Annals of Oncology)
Source: MedWorm: Oral Cancer
Tags: >=70, Advanced, Cancer, Elderly, lung, nonsmallcell, Oral, patients, performance, Phase, Poor, singleagent, Status, Trial, vinorelbine, years
Posted in Treatment | No Comments »
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Dr. Claire Verschraegen of the University of New Mexico, Albuquerque, lead author of the abstract on the palifosfamide study entitled, “A phase II randomized controlled trial of palifosfamide plus doxorubicin vs. doxorubicin in patients with soft tissue sarcoma (PICASSO)”, will present in an oral session at the American Society of Clinical Oncology (ASCO) Annual Meeting on Monday, June 7th at 2:15 pm in the Vista Room (location S 406). The abstract has been selected as part of the 2010 Best of ASCO® educational program… (Source: Health News from Medical News Today)
Source: MedWorm: Oral Cancer
Tags: ASCO, Further, Oral, Palifosfamide, Phase, PICASSO, Present, Results, Session, ZIOPHARM
Posted in Treatment | No Comments »
Marshall Edwards, Inc., (NASDAQ: MSHL). An abstract titled “A phase II study of oral phenoxodiol in castrate and non-castrate prostate cancer patients with associated cytokine changes” by Dr Kevin Kelly at the Yale School of Medicine Department of Medical Oncology, is now available at http://www.asco.org (abstract # 4661). The findings from this study in which safety and efficacy of phenoxodiol in both early (pre-metastatic) and late stage disease has been compared will be presented June 7, 2010 at the Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, Illinois… (Source: Health News from Medical News Today)
Source: MedWorm: Oral Cancer
Tags: ASCO, Cancer, Clinical, Edwards, Marshall, Phase, Phenoxodiol, Presented, Prostate, Report, Study
Posted in Treatment | No Comments »
Exelixis, Inc. (NASDAQ:EXEL) reported promising interim data from an ongoing phase 2 trial of XL184 in patients with recurrent glioblastoma (GB), the most common and aggressive form of brain cancer. Dr. Patrick Wen from the Dana Farber Cancer Institute in Boston, MA will present the data in an Oral Session (Abstract #2006) on Saturday, June 5 at 5:00 p.m. at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago… (Source: Health News from Medical News Today)
Source: MedWorm: Oral Cancer
Tags: ASCO, Data, Exelixis, glioblastoma, patients, Phase, Presented, recurrent, Reports, Updated, XL184
Posted in Treatment | No Comments »
